A carregar...
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
BACKGROUND: Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma (ESCC). The incorporation of an immune checkpoint inhibitor and a molecular anti‐angiogenic agent into the commonly adopted chemotherapy may produce synergistic effects. Therefore, we...
Na minha lista:
| Publicado no: | Cancer Commun (Lond) |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7743020/ https://ncbi.nlm.nih.gov/pubmed/33314747 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cac2.12119 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|